Alnylam Pharmaceuticals Inc NASDAQ NMS - GLOBAL MARKET:ALNY
The leadership team, board of directors, and 10% beneficial owners of Alnylam Pharmaceuticals Inc, reconstructed from SEC insider filings and proxy statements.
Other Reporting Persons
Other Section-16 reporting persons associated with the issuer.
Ausiello Dennis A
—3,500 sharesBONNEY MICHAEL W
—4,000 sharesFitzgerald Kevin Joseph
—537 sharesGarg Pushkal
—431 sharesGreenstreet Yvonne
—407 sharesPoulton Jeffrey V.
—57 sharesPYOTT DAVID E I
—27,900 sharesSHARP PHILLIP A
—266,899 sharesSigal Charles Elliott
—2,000 shares
Recent Form 4 Activity last 90 days
No insider transactions in the last 90 days.
View all insider tradesMethodology
Officers and directors are derived from SEC Forms 3, 4, and 5 filed by reporting persons for this issuer. The roster reflects the most recent disclosed relationship per individual. Officer titles use the issuer-supplied designation from the relationship record.
Independence flags and board committee assignments are sourced from the most recent DEF 14A proxy statement when available. For executive compensation context — base salary, equity grants, performance metrics — refer to the Summary Compensation Table in the issuer's annual proxy.
Cross-references: where a reporting person is matched to a consolidated people profile (same CIK across multiple issuers), the person link routes to the unified profile page so you can see every board seat and officer role in one place.